LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
6.72
-0.07 (-1.03%)
Jun 10, 2026, 11:42 AM EDT - Market open
LENZ Therapeutics Revenue
LENZ Therapeutics had revenue of $1.90M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $20.99M. In the year 2025, LENZ Therapeutics had annual revenue of $19.09M.
Revenue (ttm)
$20.99M
Revenue Growth
n/a
P/S Ratio
10.14
Revenue / Employee
$138,086
Employees
152
Market Cap
210.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.09M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 15.00M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 75.11M |
| Q32 Bio | 53.74M |
| Coherus Oncology | 46.88M |
| Foghorn Therapeutics | 28.22M |
| Adagene | 7.67M |
| Fate Therapeutics | 6.32M |
| Entrada Therapeutics | 5.74M |
| AC Immune | 4.62M |
LENZ News
- 2 days ago - Lenz announces Everest Medicines acquired rights to develop VIZZ in China - TheFly
- 2 days ago - LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China - GlobeNewsWire
- 15 days ago - LENZ Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Lenz Therapeutics price target lowered to $20 from $26 at Citi - TheFly
- 4 weeks ago - LENZ Therapeutics trading halted, volatility trading pause - TheFly
- 4 weeks ago - LENZ Therapeutics trading resumes - TheFly
- 4 weeks ago - Lenz Therapeutics price target raised to $31 from $29 at BofA - TheFly
- 4 weeks ago - Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright - TheFly